NEW YORK (GenomeWeb) – Foundation Medicine said today that it has received approval from the New York State Clinical Laboratory Evaluation Program for its FoundationACT blood-based circulating tumor DNA assay. All of its genomic profiling tests are now available in all 50 states, the company said.